Ondine Announces Publication of Positive Results from Pseudomonas aeruginosa Eradication Study

    VANCOUVER, Aug. 7 /CNW/ - Ondine Biopharma Corporation (TSX: OBP; AIM:
OBP), a medical technology company developing photodisinfection-based
products, today announced that the results of a study using the Company's
platform Photodisinfection technology to eliminate Pseudomonas aeruginosa will
be published in the peer-reviewed journal Photochemistry and Photobiology.
    The article has been e-published ahead of the print version and is
currently available online at
    P. aeruginosa is an opportunistic pathogen renowned for its ability to
live in practically any environment, including distilled water or even some
hospital disinfectant solutions. It is notorious for being resistant to almost
all antibiotics, and it is often the source of intractable infections in
cystic fibrosis patients where the fatality rate can approach 50%. In the
recently published article entitled, "In Vitro Photodynamic Eradication of
Pseudomonas aeruginosa in Planktonic and Biofilm Culture", Ondine researchers
conclusively demonstrated rapid eradication of P. aeruginosa in both
free-floating (planktonic) and the highly-resistant biofilm forms.
    "We believe that Ondine's platform photodisinfection technology can scale
to address numerous clinically unmet needs," stated Dr. Cale Street, Ondine's
Director of Research. "Pseudomonads can cause dangerous infections in humans
including respiratory infections, burn and wound infections, bacteremias,
severe external ear infections, and bone and joint infections. Pseudomonads
are one of the most difficult-to-kill microorganisms. Our photodisinfection
technology has proven capable of eradicating this virulent pathogen in short
time periods, without producing dangerous by-products. In addition,
Photodisinfection does not induce the bacterial resistance factors that
compromise antibiotics today. Our recent publication highlights the rigorous
approach we take to research and development, and adds to the peer-reviewed
literature available to our potential strategic partners for additional
photodisinfection indications."

    About Ondine Biopharma Corporation

    Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on developing and commercializing leading edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance. The Company is based in Vancouver, British Columbia,
Canada, with a research laboratory in Bothell, Washington, and an
international office in St Michael, Barbados. For additional information,
please visit the Company's website at: www.ondinebiopharma.com

    Forward-Looking Statements:

    Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's filings.

    The TSX Exchange has not reviewed and does not accept responsibility for
    the adequacy or accuracy of this release.

For further information:

For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
ccross@ondinebiopharma.com; Adam Peeler, Investor Relations, The Equicom Group
Inc., (416) 815-0700 ext. 225, apeeler@equicomgroup.com; Canaccord Adams Ltd,
Nominated Adviser & Broker, Neil Johnson, Ryan Gaffney, +4420 7050 6500

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890